证券代码：300601 证券简称：康泰生物 公告编号：2026-001 债券代码：123119 债券简称：康泰转 2 深圳康泰生物制品股份有限公司 2025 年第四季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、"康泰转2"（债券代码：123119）转股期限为2022年1月21日至2027年7 月14日，目前最新转股价格为人民币15.73元/股。 2、2025年第四季度，共有42张"康泰转2"完成转股（票面金额共计4,200 元人民币），合计转为264股"康泰生物"股票（股票代码：300601）。 3、截至2025年第四季度末，公司剩余可转债为19,989,910张，剩余票面总 金额为1,998,991,000元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第15号——可转换公司债券》的有关规定，深圳康泰生物制品股份 有限公司（以下简称"公司"）现将2025年第四季度可转换公司债券（以下简称 "可转债"）转股及公司总股本变化情况公告如下： 一、可转债发行上市基本情况 （ ...

在AI技术驱动下，实验室重点推进两大方向：一是以AI辅助精准免疫原设计，实现从免疫机制到功能 表位的闭环研究，为精准疫苗设计奠定分子基础；二是依托变异监测+AI结构疫苗学技术，破解病原变 异快、血清型多难题，实现"一苗防多病"(RSV-hMPV二联苗等)。 据康泰生物（300601）官微消息，近日"合成免疫学与疫苗智造北京市重点实验室"在北京正式揭牌。该 实验室以中国科学院微生物所为依托单位，康泰生物全资子公司民海生物、馨智生物、成大天和联合共 建，聚焦合成免疫学与疫苗智造关键问题开展深度合作。 在产业化层面，实验室致力于突破新型疫苗制备工艺关键技术瓶颈，推动关键设备及物料国产化，同步 实现产能显著提升，力争在研发与生产环节实现全球领跑。 作为国内疫苗行业龙头企业，康泰生物深度参与该实验室建设，将AI技术贯穿疫苗研发全链条作为核 心突破方向。根据规划，该实验室将致力于实现抗原设计、佐剂开发、递送系统与质控等基础理论突 破，攻克多联多价疫苗免疫干扰与抗原兼容性瓶颈，建立国际领先的疫苗快速响应与智能制造体系。 当前，生物医药产业的全球竞争已超越了单一企业或科研机构的范畴，升级为全链条创新生态系统的较 量。此次产学 ...

人民财讯1月5日电，据康泰生物（300601）消息，近日，"合成免疫学与疫苗智造北京市重点实验室"揭 牌仪式在北京举行。该实验室以中国科学院微生物所为依托单位，康泰生物全资子公司民海生物、馨智 生物、成大天和三家企业联合共建，聚焦合成免疫学与疫苗智造关键问题开展深度合作。 ...

Group 1 - The core point of the article highlights the trading performance of Kangtai Biological, which experienced a slight decline of 0.61% on December 31, closing at 14.77 yuan [1] - The stock recorded a significant block trade with a total volume of 496,600 shares and a transaction amount of 7.3345 million yuan, with a premium rate of 0.00% [1] - Over the past three months, Kangtai Biological has seen a total of two block trades, amounting to 14.4226 million yuan [1] Group 2 - In the last five trading days, the stock has cumulatively decreased by 2.25%, with a total net outflow of 34.4401 million yuan from major funds [1]

每经头条（nbdtoutiao）——绕开光刻机"卡脖子"，中国新型芯片问世！专访北大孙仲：支撑AI训练和 具身智能，可在28纳米及以上成熟工艺量产 （记者 王晓波） 每经AI快讯，康泰生物（SZ 300601，收盘价：14.98元）发布公告称，2025年12月25日，康泰生物接受 华安基金等投资者调研，公司投资者关系总监吴华参与接待，并回答了投资者提出的问题。 2024年1至12月份，康泰生物的营业收入构成为：生物制品占比98.31%，其他业务收入占比1.69%。 截至发稿，康泰生物市值为167亿元。 ...

Group 1: Vaccine Development Progress - The five-component vaccine is currently in Phase III clinical trials, making it the fastest progressing domestic five-component vaccine in China, aiming to break the import monopoly [1] - The recombinant hepatitis B vaccine for chronic hepatitis B patients has received clinical trial approval, targeting a population of approximately 75 million chronic HBV carriers in China [2] - The company is also developing a Klebsiella pneumoniae vaccine to address antibiotic-resistant bacteria, which is a significant global public health challenge [3] Group 2: Market Potential and Growth - The global chronic hepatitis B infection rate is approximately 254 million, with a prevalence rate of 5% to 7% in China, indicating a substantial unmet clinical need [2] - The hepatitis B virus drug market in China is projected to exceed 70 billion yuan by 2030, with an annual compound growth rate of 18% from 2019 to 2030 [2] - The adult vaccination market in China remains underdeveloped compared to developed countries, presenting significant growth opportunities as public awareness increases [3] Group 3: Research and Development Investment - In the first half of 2025, the company invested 334 million yuan in R&D, accounting for 23.96% of its revenue, a 41.52% increase from the same period in 2024 [4] - The company is advancing multiple vaccine candidates, including the four-valent influenza vaccine and the five-component vaccine, with several in various clinical trial phases [5] Group 4: International Expansion - The company is expanding its international presence through partnerships in over 20 countries, focusing on product registration and commercialization [6] - In the first three quarters of 2025, overseas revenue reached 41.9 million yuan, a 324.27% increase year-on-year [7] Group 5: Future Development Strategy - The company plans to enhance its market presence through "internal innovation + external expansion," focusing on core pipeline advantages and optimizing sales networks [8] - Continuous R&D investment will drive the development of multi-component, adult, innovative, and therapeutic vaccines, aiming to build a competitive product matrix [9] Group 6: Shareholder Returns - In June 2025, the company distributed cash dividends amounting to 101 million yuan, representing 49.85% of the net profit attributable to shareholders for 2024 [9] - Since its listing in 2017, the company has distributed a total of 1.885 billion yuan in cash dividends, accounting for 44.66% of the total net profit attributable to shareholders [9]

Group 1 - Jizhi Co., Ltd. plans to acquire at least 51% equity in Pumai Technology through cash payment, aiming to gain control over the company, which is a leading enterprise in the field of robot performance testing and calibration in China [1] - Yaxing Chemical's subsidiary intends to transfer 7.14% equity for 60 million yuan to another fund under the same control, indicating strategic investment movements within the same management group [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Sentai Co., Ltd.'s controlling shareholder plans to increase shareholding by at least 100 million yuan within 12 months, aiming to enhance confidence in the company's future [4] - Health元's subsidiary has received acceptance for the marketing authorization application of Lecanemab injection, which is intended for moderate to severe plaque psoriasis patients [5][11] - Sunshine Nuohuo has signed a technical development contract for the STC008 injection project, with a total payment of 500 million yuan, indicating significant investment in cancer treatment [6] Group 3 - Hunan YN has been designated as a delivery warehouse for lithium carbonate by the Guangzhou Futures Exchange, enhancing its position in the lithium market [7] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, although it faces risks in commercialization [8] - Yuandong Bio has received FDA approval for Methylene Blue injection, expanding its product portfolio in the U.S. market [10] Group 4 - Nanshan Aluminum has established a wholly-owned subsidiary in Hainan with an investment of 5 million yuan, focusing on high-end aluminum products [13] - ST Xifa plans to acquire 50% equity in Lhasa Beer, aiming for full ownership, with the transaction currently in the planning stage [14] - Hengrui Medicine's SHR-A1904 injection has been included in the list of breakthrough therapy products, indicating its potential in treating advanced gastric cancer [12] Group 5 - Chengdu Gas is planning to merge three subsidiaries, streamlining operations and enhancing efficiency [26] - Baoli Electric intends to invest 50 million yuan to establish a wholly-owned subsidiary focused on key equipment and solutions in energy storage [27] - Huadian International has successfully put the second unit of its Longkou Phase IV project into commercial operation, marking a significant milestone in its energy production capacity [34]

格隆汇12月24日丨康泰生物(300601.SZ)公布，全资子公司北京民海生物科技有限公司（简称"民海生 物"）研发的吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗（简称"五联疫苗"）已完成 Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。五联疫苗用于预 防白喉、破伤风、百日咳、脊髓灰质炎和b型流感嗜血杆菌引起的侵入性感染，具有减少婴幼儿的接种 针次，增强家长和婴幼儿接种的依从性等优势。 ...

康泰生物公告，全资子公司北京民海生物科技有限公司研发的吸附无细胞百白破灭活脊髓灰质炎和b型 流感嗜血杆菌联合疫苗（简称"五联疫苗"）已完成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并 于今日成功完成首例受试者入组。五联疫苗用于预防白喉、破伤风、百日咳、脊髓灰质炎和b型流感嗜 血杆菌引起的侵入性感染，具有减少婴幼儿的接种针次，增强家长和婴幼儿接种的依从性等优势。 ...

每经AI快讯，12月24日，康泰生物(300601.SZ)公告称，公司全资子公司民海生物研发的五联疫苗已完 成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并成功完成首例受试者入组。五联疫苗用于预防白 喉、破伤风、百日咳、脊髓灰质炎和b型流感嗜血杆菌引起的侵入性感染。 ...